Prescription of oral hypoglycemic agents for patients with type 2 diabetes mellitus: A retrospective cohort study using a Japanese hospital database

Journal of Diabetes Investigation

Volumn 8, Issue 2, 2017, Pages 227-234

  Tanabe, Makito ^a   Motonaga, Ryoko ^a   Terawaki, Yuichi ^a   Nomiyama, Takashi ^a   Yanase, Toshihiko ^a  

^a FUKUOKA UNIVERSITY   (Japan)

Author keywords

Cardiovascular disease; Oral hypoglycemic agent; Type 2 diabetes mellitus

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALPHA GLUCOSIDASE INHIBITOR; BIGUANIDE DERIVATIVE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLINIDE DERIVATIVE; HEMOGLOBIN A1C; ORAL ANTIDIABETIC AGENT; PRESCRIPTION DRUG; SULFONYLUREA DERIVATIVE; UNCLASSIFIED DRUG; 2,4-THIAZOLIDINEDIONE; ANTIDIABETIC AGENT; GLYCOSIDASE INHIBITOR; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN;

ADOLESCENT; AGED; ALGORITHM; ARTICLE; CARDIOVASCULAR DISEASE; COHORT ANALYSIS; CONTROLLED STUDY; DATA BASE; DRUG EFFECT; FEMALE; HEMOGLOBIN BLOOD LEVEL; HOSPITAL; HUMAN; JAPANESE (PEOPLE); MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT COMPLIANCE; PRESCRIPTION; RETROSPECTIVE STUDY; BLOOD; DIABETES MELLITUS, TYPE 2; FACTUAL DATABASE; JAPAN; METABOLISM; MIDDLE AGED; ORAL DRUG ADMINISTRATION; STATISTICS AND NUMERICAL DATA;

ADMINISTRATION, ORAL; AGED; DATABASES, FACTUAL; DIABETES MELLITUS, TYPE 2; DRUG PRESCRIPTIONS; FEMALE; GLYCOSIDE HYDROLASE INHIBITORS; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; JAPAN; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; THIAZOLIDINEDIONES;

EID: 84993996068     PISSN: 20401116     EISSN: 20401124     Source Type: Journal    
DOI: 10.1111/jdi.12567     Document Type: Article

References (36)

1. de Marco R, Locatelli F, Zoppini G, et al. Cause-specific mortality in type 2 diabetes. The Verona Diabetes Study. Diabetes Care 1999; 22: 756–761.
2. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34. Lancet 1998; 352: 854–865).
3. Bolen S, Feldman L, Vassy J, et al. Systematic review: comparative effectiveness and safety of oral medications for type 2 diabetes mellitus. Ann Intern Med 2007; 147: 386–399.
4. Chiasson JL, Josse RG, Gomis R, et al. STOP-NIDDM Trial Research Group: Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA 2003; 290: 486–494.
5. Hanefeld M, Cagatay M, Petrowitsch T, et al. Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studies. European Heart J 2004; 25: 10–16.
6. Mazzone T, Meyer PM, Feinstein SB, et al. Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial. JAMA 2006; 296: 2572–2581.
7. Nissen SE, Nicholls SJ, Wolski K, et al. Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. JAMA 2008; 299: 1561–1573.
8. Ussher JR, Drucker DJ. Cardiovascular biology of the incretin system. Endocr Rev 2012; 33: 187–215.
9. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med 2015; 373: 2117–2128.
10. American Diabetes Association. Standards of medical care in diabetes 2012. Diabetes Care 2012; 35(Suppl. 1): S11–S63.
11. Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein HC, Miller ME, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358: 2545–2559.
12. ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358: 2560–2572.
13. Duckworth W, Abraira C, Moritz T, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009; 360: 129–139.
14. Tanabe M, Nomiyama T, Motonaga R, et al. Reduced vascular events in type 2 diabetes by biguanide relative to sulfonylurea: study in a Japanese Hospital Database. BMC Endocr Disord 2015; 15: 49.
15. Chan JC, Tomlinson B, Critchley JA, et al. Metabolic and hemodynamic effects of metformin and glibenclamide in normotensive NIDDM patients. Diabetes Care 1993; 16: 1035–1038.
16. Mandavilli A, Cyranoski D. Asia's big problem. Nat Med 2004; 10: 325–327.
17. Geier AS, Wellmann I, Wellmann J, et al. Patterns and determinants of new first-line antihyperglycaemic drug use in patients with type 2 diabetes mellitus. Diabetes Res Clin Pract 2014; 106: 73–80.
18. Hampp C, Borders-Hemphill V, Moeny DG, et al. Use of antidiabetic drugs in the U.S., 2003–2012. Diabetes Care 2014; 37: 1367–1374.
19. Nomiyama T, Akehi Y, Takenoshita H, et al. Contributing factors related to efficacy of the dipeptidyl peptidase-4 inhibitor sitagliptin in Japanese patients with type 2 diabetes. Diabetes Res Clin Pract 2012; 95: e27–e28.
20. Terawaki Y, Nomiyama T, Akehi Y, et al. The efficacy of incretin therapy in patients with type 2 diabetes undergoing hemodialysis. Diabetol Metab Syndr 2013; 5: 10.
21. Terawaki Y, Nomiyama T, Takahashi H, et al. Efficacy of dipeptidyl peptidase-4 inhibitor linagliptin in patients with type 2 diabetes undergoing hemodialysis. Diabetol Metab Syndr 2015; 7: 44.
22. Ahrén B. DPP-4 inhibitors. Best Pract Res Clin Endocrinol Metab 2007; 21: 517–533.
23. Cho YM, Kieffer TJ. New aspects of an old drug: metformin as a glucagon-like peptide 1 (GLP-1) enhancer and sensitiser. Diabetologia 2011; 54: 219–222.
24. Mannucci E, Ognibene A, Cremasco F, et al. Effect of metformin on glucagon-like peptide 1 (GLP-1) and leptin levels in obese nondiabetic subjects. Diabetes Care 2001; 24: 489–494.
25. Lindsay JR, Duffy NA, McKillop AM, et al. Inhibition of dipeptidyl peptidase IV activity by oral metformin in Type 2 diabetes. Diabet Med 2005; 22: 654–657.
26. Migoya EM, Bergeron R, Miller JL, et al. Dipeptidyl peptidase-4 inhibitors administered in combination with metformin result in an additive increase in the plasma concentration of active GLP-1. Clin Pharmacol Ther 2010; 88: 801–808.
27. Lee A, Patrick P, Wishart J, et al. The effects of miglitol on glucagons-like peptide-1 secretion and appetite sensations in obese type 2 diabetics. Diabetes Obes Metab 2002; 4: 329–335.
28. Bergstrom RW, Wahl PW, Leonetti DL, et al. Association of fasting glucose levels with a delayed secretion of insulin after oral glucose in subjects with glucose intolerance. J Clin Endocrinol Metab 1990; 71: 1447–1453.
29. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837–853.
30. Kahn SE, Haffner SM, Heise MA, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006; 355: 2427–2443.
31. Ceriello A, Colaqiuri S, Gerich J, et al. Guideline for management of postmeal glucose. Nutur Metab Cardiovasc Dis 2008; 18: S17–S33.
32. Roumie CL, Hung AM, Greevy RA, et al. Comparative effectiveness of sulfonylurea and metformin monotherapy on cardiovascular events in type 2 diabetes mellitus: a cohort study. Ann Intern Med 2012; 157: 601–610.
33. Hara T, Nakamura J, Koh N, et al. An importance of carbohydrate ingestion for the expression of the effect of alpha-glucosidase inhibitor in NIDDM. Diabetes Care 1996; 19: 642–647.
34. Scirica BM, Bhatt DL, Braunwald E, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 2013; 369: 1317–1326.
35. White WB, Cannon CP, Heller SR, et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 2013; 369: 1327–1335.
36. Green JB, Bethel MA, Armstrong PW, et al. Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med 2015; 373: 232–242.